Luxia Scientific partners with Life Genomics to commercialize microbiome-based tests in the Nordic countries

Luxia Scientific, a French biotech dedicated to improving wellbeing and health for all through the analysis and understanding of the microbiome, announced today that it has signed an exclusive distribution agreement with Life Genomics to commercialize « 1test1TM » in Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). The test was launched in France in October 2018 and in Luxembourg in November 2018.

Reminder:

« 1test1TM » is a CE-marked In Vitro Diagnostics test, aimed at analysing the bacterial content of the gut microbiome. « 1test1TM » provides bacterial diversity, as well as the relative abundance of many bacterial groups that have been selected for their beneficial role in health.

Luxia Scientific by signing an exclusive distribution agreement with Life Genomics expands its market to the Nordic countries. Life Genomics will be the official distributor of the test in Sweden, where this company is based, and also in Denmark, Finland, Iceland and Norway. The list of outlets will be directly available on their website (http://www.lifegenomics.se/).

Our partnership with Life Genomics is a recognition of the quality of our products and our expertise in metagenomics. We are looking forward to working together and to extend the sales of 1test1TM to the Scandinavian market. This partnership will allow more clients to benefit from a personalized approach based on their gut microbiome. Life Genomics is leading the Nordic market with its genetic tests aimed at the public.”

Alessandra Cervino, CEO of Luxia Scientific

The Scientists behind Luxia Scientific have studied the microbiome for more than 10 years and are amongst the most experienced in the field. We feel very comfortable with their support to us and well-founded recommendations how conditions may be improved by dietary and life style changes to those with dysbiosis. The 1test1TM is a perfect complement to our portfolio of genetic tests for preventive healthcare.”

Göran Jacobsson, CEO of Life Genomics

Source: https://www.luxia-scientific.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Luxia Scientific. (2019, March 25). Luxia Scientific partners with Life Genomics to commercialize microbiome-based tests in the Nordic countries. News-Medical. Retrieved on July 23, 2019 from https://www.news-medical.net/news/20190325/Luxia-Scientific-partners-with-Life-Genomics-to-commercialize-microbiome-based-tests-in-the-Nordic-countries.aspx.

  • MLA

    Luxia Scientific. "Luxia Scientific partners with Life Genomics to commercialize microbiome-based tests in the Nordic countries". News-Medical. 23 July 2019. <https://www.news-medical.net/news/20190325/Luxia-Scientific-partners-with-Life-Genomics-to-commercialize-microbiome-based-tests-in-the-Nordic-countries.aspx>.

  • Chicago

    Luxia Scientific. "Luxia Scientific partners with Life Genomics to commercialize microbiome-based tests in the Nordic countries". News-Medical. https://www.news-medical.net/news/20190325/Luxia-Scientific-partners-with-Life-Genomics-to-commercialize-microbiome-based-tests-in-the-Nordic-countries.aspx. (accessed July 23, 2019).

  • Harvard

    Luxia Scientific. 2019. Luxia Scientific partners with Life Genomics to commercialize microbiome-based tests in the Nordic countries. News-Medical, viewed 23 July 2019, https://www.news-medical.net/news/20190325/Luxia-Scientific-partners-with-Life-Genomics-to-commercialize-microbiome-based-tests-in-the-Nordic-countries.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post